MRFR Year End Sale
Anal Cancer Market Research Report - Forecast till 2030

Anal Cancer Market Research Report: Information by Cancer Type (Carcinoma in Situ, Squamous Cell Carcinoma, Adenocarcinoma, Basal Cell Carcinoma, Melanoma and others), Treatment Type (Chemotherapy, Surgery, Radiation Therapy and Immunotherapy), End User (Hospitals & Clinics, Research & Academic Institutes and others) - Forecast till 2030

ID: MRFR/MED/1001-HCR | December 2022 | Region: Global | 130 Pages         

Anal Cancer Market Speak to Analyst Request a Free Sample

Anal Cancer Market Overview

The Anal cancer market is anticipated to reach USD 1,638.5 Million by 2030 at 8.6% CAGR during the forecast period 2022-2030.
Anal cancer is a rare type of cancer that begins in the anus, which is the orifice at the rectum's end. Anal cancer has one of the highest rates of occurrence and prevalence in the globe. Lifestyle issues, aging, and diet are thought to be the primary causes of anal cancer. According to the World Health Organization (WHO), an increase of roughly 70% in anal cancer cases is projected globally over the Anal Cancer Market Analysis period.

Squamous cell carcinoma, which develops from cells around or in the anal entrance or, in rare cases, in the anal canal, is the most common type of anal cancer. This malignancy is frequently linked to the human papillomavirus (HPV), with HPV malignancies or cervical cancers having a significant chance of progressing to anal cancer. Anal cancer has no specific symptoms, however, it might cause bleeding from the anal area, a tumor or swelling near the anus, or a change in bowel habits. Tumor, node, and metastasis are divided into I, II, IIIA, IIIB, and IV stages, which are further divided into I, II, IIIA, IIIB, and IV. Melanoma, adenocarcinoma, basal cell carcinoma, and gastrointestinal stromal tumor (GIST) are the main types of anal cancer, and most people with anal cancer are treated with chemoradiation, which is a mix of chemotherapy and radiation. Combining therapy raises the likelihood of a successful cure and is expected to grow during the Anal Cancer Market Forecast period.

COVID Analysis

The COVID-19 epidemic has wreaked havoc on healthcare systems around the world, as well as the anal cancer industry. Cancer screening and other health prevention services, as well as elective surgeries, should be postponed unless the risks outweighed the benefits, according to the Centers for Disease Control and Prevention (CDC) and many medical professional organizations, to secure the hospital infrastructure for the treatment of COVID-19 patients. As a result, the COVID-19 pandemic has influenced ongoing clinical trials. The situation, though, is likely to progressively improve and increase Anal Cancer Market Growth. COVID-19 has resulted in a significant increase in demand for ventilators, in contrast to market Growth, and manufacturers are currently focusing their efforts on satisfying the increased need for ventilators, as well as other types of equipment. The high rate of sexual intercourse is expected to grow and increase Anal Cancer Market Outlook.

Anal Cancer Market Dynamics

Drivers

Anal Cancer Market Value is predicted to be fueled by factors such as the rising prevalence of anal cancer and the rising number of sexually transmitted illnesses. An anticipated 8,300 additional cases of anal cancer were detected during the historical prediction period, according to a report released by the American Cancer Society. Females are responsible for around 5,530 of these incidents. In the last several years, the number of cases of anal cancer has increased. There will be approximately 9,090 new cases in the United States. Anal cancer is uncommon in those under the age of 35 and is mostly diagnosed in older adults, with an average age in the early 60s. Furthermore, growing oncology research and development spending are likely to promote Anal Cancer Market Trends. The government's increasing initiatives to raise public awareness about anal malignancies are the primary drivers of the market.

Anal cancer is a type of cancer that affects the colon and rectum. The income earned by medications used to treat anal cancer, as well as other screening tests, kits, and medical devices used to diagnose colorectal cancer, is tracked in the study. The high spending on public health initiatives, as well as the rapid rise in global healthcare expenditure and research and development expenditure in the field of oncology, are projected to provide substantial potential prospects and increase the market size.

Restraints

However, the treatment's negative effects and a lack of knowledge are projected to stifle Anal Cancer Market Trends. The market's expansion is projected to be hampered by high treatment costs. According to the American Cancer Society, the cost of anal cancer treatment in India ranges from USD 1500 to USD 15,000, which is a significant burden for emerging and impoverished countries. One of the primary reasons limiting market Share is this. Inadequate reimbursement and a scarcity of competent experts, on the other hand, may limit the market value.

Anal Cancer Market Segment Overview

The Global Anal Cancer Market is segmented by cancer type, treatment type and end user are based on the following:

Based on the cancer type, the market has been segmented as follows:



  • Carcinoma In Situ

  • Squamous Cell Carcinoma

  • Melanoma

  • Adenocarcinoma

  • Basal Cell Carcinoma

  • Others



Based on the treatment type, the market has been segmented as follows:



  • Chemotherapy

  • Surgery

  • Radiation Therapy

  • Immunotherapy



Based on the end-user, the market has been segmented as follows:



  • Hospitals & Clinics

  • Research & Academic Institutes

  • Others



Anal Cancer Market Regional Classification

The Americas are likely to lead the anal cancer market because of the increased prevalence of anal cancer. According to the American Cancer Society, around 1,280 persons will die of anal cancer during the forecast period.

Europe is predicted to represent the second-largest share of the anal cancer market because of the increased prevalence of anal cancer and the presence of significant market participants. During the historic forecast period, 1,438 new cases of anal cancer were discovered in the UK, according to Cancer Research UK.

Asia-Pacific is predicted to be the fastest-growing regional market due to expanding cancer awareness and the incidence of sexually transmitted illnesses.

In The Middle East and Africa, due to the high incidence rate of anal cancer, the market is likely to develop gradually throughout the forecast period.

Americas



  • North America

    • US

    • Canada



  • Latin America



Europe



  • Western Europe

    • Germany

    • France

    • Italy

    • Spain

    • UK



  • Rest of Western Europe

  • Eastern Europe



Asia-Pacific



  • Japan

  • China

  • India

  • Australia

  • South Korea



  • Rest of Asia-Pacific



The Middle East & Africa



  • Middle East



Africa

Anal Cancer Market Competitive Landscape

Due to the presence of many small and large market players, the industry analyzed is fairly consolidated. Furthermore, several new biotech companies are entering the therapeutics market by releasing new drugs and collaborating and acquiring other companies in the global anal cancer market. The major key players of the market are Amgen Inc. (US), Eli Lilly and Company (US), Bristol-Myers Squibb Company (US), Merck & Co., Inc. (the US), Novartis AG (Switzerland), Celgene Corporation (US), Pfizer Inc. (US), Sanofi (France), GlaxoSmithKline plc (UK), Johnson & Johnson Services, Inc. (the US), F. Hoffmann-La Roche Ltd (Switzerland), and Hospira, Inc. (the US).

Recent Developments

The Phase II Study of Docetaxel, Cisplatin, and 5-fluorouracil in Combination or Not with Atezolizumab in Patients with Metastatic or Unresectable Locally Advanced Squamous Cell Anal Carcinoma, which Roche Pharma AG is conducting.

Hoffmann-La Roche Ltd develops cutting-edge medications and diagnostic tests that benefit millions of people across the world. Roche was one of the first pharmaceutical corporations to provide patients with targeted therapy. They are more suited than any other company to advance personalized healthcare due to their combined strength in drugs and diagnostics.

Report Overview

The study highlights the important commercial assets and players in the Anal Cancer Market segmentation by Cancer type, Treatment type, End-users, and geography. It also analyses trends and co-development arrangements to identify business opportunities in the market. The report contains the most up-to-date analysis, which was compiled after conducting extensive qualitative interviews and doing a thorough market analysis. This report also includes information on market drivers, restraints, new product launches or approvals, market trends, regional outlooks, and key players' competitive strategies. Company overview, financial performance, product portfolio, market presence, distribution strategies, important advancements, strategies, and plans are used to profile key players in the global market.



Report Scope:

Report Attribute/Metric Details
  Market Size   2030 : USD 1,638.5 Million
  CAGR   8.6% (2022-2030)
  Base Year   2021
  Forecast Period   2022-2030
  Historical Data   2020
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Information by Cancer Type, Treatment Type, End User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Amgen Inc. (US), Bristol-Myers Squibb Company (US), Celgene Corporation (US), Eli Lilly and Company (US), F. Hoffmann-La Roche Ltd (Switzerland), Merck & Co., Inc. (US), Novartis AG (Switzerland), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Sanofi (France), Johnson & Johnson Services, Inc. (US) and Hospira, Inc. (US)
  Key Market Opportunities   New product launches and R&D Amongst major key Players
  Key Market Drivers

  • Rising prevalence of anal cancer
  • The growing number of sexually transmitted diseases


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    Anal cancer market valuation was USD 1,638.5 Million

    Anal cancer market CAGR would be 8.6% during the forecast period.

    Anal cancer market top players are Celgene Corporation (US), Amgen Inc. (US), Bristol-Myers Squibb Company (US), F. Hoffmann-La Roche Ltd (Switzerland), Eli Lilly and Company (US), Pfizer Inc. (US), Merck & Co., Inc. (US), Novartis AG (Switzerland), Sanofi (France), Johnson & Johnson Services, Inc. (US,) GlaxoSmithKline plc (UK), and Hospira, Inc. (US)

    Anal cancer market in the Americas would be the largest.

    The Asia Pacific region would be the fastest-growing region for anal cancer market.